Trials / Completed

CompletedNCT06467981

Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)

Study of the Indications for Amyloid PET Scans and Their Usefulness in the Management of Patients With Suspected Alzheimer's Disease (AD)

Status: Completed
Phase: —
Study type: Observational
Enrollment: 160 (actual)

Sponsor: Central Hospital, Nancy, France · Academic / Other
Sex: All
Age: 18 Years – 99 Years
Healthy volunteers: Not accepted

Summary

Detailed description

The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD). At the era of Amyloid, Tau, Neurodegeneration (ATN) biomarkers, amyloid PET fills a need in patients with an atypical or mixed clinical presentation, in particular young patients (\< 65 years old), when the lumbar puncture is contraindicated or not feasible for technical reasons. Importantly, a negative amyloid PET scan discards the diagnosis of AD. Furthermore, early phase imaging of amyloid PET allows to estimate the perfusion neuronal state, increasing the diagnostic value of such PET radiotracer. Its role could be further developed in routine care for the selection and monitoring of promising disease modifiers therapies.

Conditions

Alzheimer Disease

Interventions

Type	Name	Description
OTHER	Retrospective study	The data from the PET request form will be collected in each center for this population of patients who have had an amyloid PET scan with flutemetamol and the results of the PET examination reports will also be provided, all data will be made anonymous.

Timeline

Start date: 2024-11-01
Primary completion: 2024-12-30
Completion: 2025-02-15
First posted: 2024-06-21
Last updated: 2025-06-05

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06467981. Inclusion in this directory is not an endorsement.